-
1
-
-
0032924934
-
Cytochrome P-450 3A4: Regulation and role in drug metabolism
-
Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 1999; 39: 1-17
-
(1999)
Annu Rev Pharmacol Toxicol
, vol.39
, pp. 1-17
-
-
Guengerich, F.P.1
-
2
-
-
0031748173
-
In vitro and in vivo drug interactions involving human CYP3A
-
Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 1998; 38: 389-430
-
(1998)
Annu Rev Pharmacol Toxicol
, vol.38
, pp. 389-430
-
-
Thummel, K.E.1
Wilkinson, G.R.2
-
3
-
-
0028126571
-
Midazolam is metabolized by at least three different cytochrome P450 enzymes
-
Wandel C, Bocker R, Bohrer H, et al. Midazolam is metabolized by at least three different cytochrome P450 enzymes. Br J Anaesth 1994; 73: 658-61
-
(1994)
Br J Anaesth
, vol.73
, pp. 658-661
-
-
Wandel, C.1
Bocker, R.2
Bohrer, H.3
-
4
-
-
0033860013
-
Involvement of CYP1A2 and CYP3A4 in lidocaine N-deethylation and 3-hydroxylation in humans
-
Wang JS, Backman JT, Taavitsainen P, et al. Involvement of CYP1A2 and CYP3A4 in lidocaine N-deethylation and 3-hydroxylation in humans. Drug Metab Dispos 2000; 28: 959-65
-
(2000)
Drug Metab Dispos
, vol.28
, pp. 959-965
-
-
Wang, J.S.1
Backman, J.T.2
Taavitsainen, P.3
-
5
-
-
0007204117
-
Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A
-
Kinirons MT, O'Shea D, Kim RB, et al. Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A. Clin Pharmacol Ther 1999; 66: 224-31
-
(1999)
Clin Pharmacol Ther
, vol.66
, pp. 224-231
-
-
Kinirons, M.T.1
O'Shea, D.2
Kim, R.B.3
-
6
-
-
0347361482
-
Urinary 6beta-hydroxycortisol: A validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals
-
Galteau MM, Shamsa F. Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals. Eur J Clin Pharmacol 2003; 59: 713-33
-
(2003)
Eur J Clin Pharmacol
, vol.59
, pp. 713-733
-
-
Galteau, M.M.1
Shamsa, F.2
-
7
-
-
17844393071
-
There are no useful CYP3A probes that quantitatively predict the in vivo kinetics of other CYP3A substrates and no expectation that one will be found
-
Benet LZ. There are no useful CYP3A probes that quantitatively predict the in vivo kinetics of other CYP3A substrates and no expectation that one will be found. Mol Interv 2005; 5: 79-83
-
(2005)
Mol Interv
, vol.5
, pp. 79-83
-
-
Benet, L.Z.1
-
8
-
-
0028933307
-
Catalytic role of cytochrome P4503A4 in multiple pathways of alfentanil metabolism
-
Labroo RB, Thummel KE, Kunze KL, et al. Catalytic role of cytochrome P4503A4 in multiple pathways of alfentanil metabolism. Drug Metab Dispos 1995; 23: 490-6
-
(1995)
Drug Metab Dispos
, vol.23
, pp. 490-496
-
-
Labroo, R.B.1
Thummel, K.E.2
Kunze, K.L.3
-
9
-
-
0027241257
-
Human alfentanil metabolism by cytochrome P450 3A3/4: An explanation for the interindividual variability in alfentanil clearance?
-
Kharasch ED, Thummel KE. Human alfentanil metabolism by cytochrome P450 3A3/4: an explanation for the interindividual variability in alfentanil clearance? Anesth Analg 1993; 76: 1033-9
-
(1993)
Anesth Analg
, vol.76
, pp. 1033-1039
-
-
Kharasch, E.D.1
Thummel, K.E.2
-
10
-
-
14044254164
-
Metabolism of alfentanil by cytochrome P4503A (CYP3A) enzymes
-
Klees TM, Sheffels P, Dale O, et al. Metabolism of alfentanil by cytochrome P4503A (CYP3A) enzymes. Drug Metab Dispos 2005; 33: 303-11
-
(2005)
Drug Metab Dispos
, vol.33
, pp. 303-311
-
-
Klees, T.M.1
Sheffels, P.2
Dale, O.3
-
11
-
-
0033009998
-
Is the role of the small intestine in first-pass metabolism overemphasized?
-
Lin JH, Chiba M, Baillie TA. Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol Rev 1999; 51: 135-58
-
(1999)
Pharmacol Rev
, vol.51
, pp. 135-158
-
-
Lin, J.H.1
Chiba, M.2
Baillie, T.A.3
-
12
-
-
0037374331
-
Disposition and miotic effects of oral alfentanil: A potential noninvasive probe for first-pass cytochrome P4503A activity
-
Kharasch ED, Hoffer C, Walker A, et al. Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity. Clin Pharmacol Ther 2003; 73: 199-208
-
(2003)
Clin Pharmacol Ther
, vol.73
, pp. 199-208
-
-
Kharasch, E.D.1
Hoffer, C.2
Walker, A.3
-
13
-
-
0035656880
-
A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans
-
Phimmasone S, Kharasch ED. A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. Clin Pharmacol Ther 2001; 70: 505-17
-
(2001)
Clin Pharmacol Ther
, vol.70
, pp. 505-517
-
-
Phimmasone, S.1
Kharasch, E.D.2
-
14
-
-
7944237810
-
Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: Noninvasive assessment by use of pupillary miosis
-
Kharasch ED, Walker A, Hoffer C, et al. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. Clin Pharmacol Ther 2004; 76: 452-66
-
(2004)
Clin Pharmacol Ther
, vol.76
, pp. 452-466
-
-
Kharasch, E.D.1
Walker, A.2
Hoffer, C.3
-
15
-
-
27844601564
-
Alfentanil-induced miosis clearance as a liver CYP3A4 and 3A5 activity measure in healthy volunteers: Improvement of experimental conditions
-
Baririan N, Horsmans Y, Desager JP, et al. Alfentanil-induced miosis clearance as a liver CYP3A4 and 3A5 activity measure in healthy volunteers: improvement of experimental conditions. J Clin Pharmacol 2005; 45: 1434-41
-
(2005)
J Clin Pharmacol
, vol.45
, pp. 1434-1441
-
-
Baririan, N.1
Horsmans, Y.2
Desager, J.P.3
-
16
-
-
1942421303
-
The effect of liver cirrhosis on the regulation and expression of drug metabolizing enzymes
-
Elbekai RH, Korashy HM, El-Kadi AO. The effect of liver cirrhosis on the regulation and expression of drug metabolizing enzymes. Curr Drug Metab 2004; 5: 157-67
-
(2004)
Curr Drug Metab
, vol.5
, pp. 157-167
-
-
Elbekai, R.H.1
Korashy, H.M.2
El-Kadi, A.O.3
-
18
-
-
0021920040
-
Alfentanil pharmacokinetics in patients with cirrhosis
-
Ferrier C, Marty J, Bouffard Y, et al. Alfentanil pharmacokinetics in patients with cirrhosis. Anesthesiology 1985; 62: 480-4
-
(1985)
Anesthesiology
, vol.62
, pp. 480-484
-
-
Ferrier, C.1
Marty, J.2
Bouffard, Y.3
-
20
-
-
0031056551
-
Quantitative liver function tests define the functional severity of liver disease in early-stage cirrhosis
-
Shrestha R, McKinley C, Showalter R, et al. Quantitative liver function tests define the functional severity of liver disease in early-stage cirrhosis. Liver Transpl Surg 1997; 3: 166-73
-
(1997)
Liver Transpl Surg
, vol.3
, pp. 166-173
-
-
Shrestha, R.1
McKinley, C.2
Showalter, R.3
-
21
-
-
0031431015
-
In vivo function tests of hepatic drug-oxidizing capacity in patients with liver disease
-
Tanaka E, Breimer DD. In vivo function tests of hepatic drug-oxidizing capacity in patients with liver disease. J Clin Pharm Ther 1997; 22: 237-49
-
(1997)
J Clin Pharm Ther
, vol.22
, pp. 237-249
-
-
Tanaka, E.1
Breimer, D.D.2
-
22
-
-
0035145285
-
Quantitative testing of liver function in patients with cirrhosis due to chronic hepatitis C to assess disease severity
-
Herold C, Heinz R, Radespiel-Troger M, et al. Quantitative testing of liver function in patients with cirrhosis due to chronic hepatitis C to assess disease severity. Liver 2001; 21: 26-30
-
(2001)
Liver
, vol.21
, pp. 26-30
-
-
Herold, C.1
Heinz, R.2
Radespiel-Troger, M.3
-
23
-
-
0036912743
-
Can quantitative tests of liver function discriminate between different etiologies of liver cirrhosis?
-
Herold C, Regn S, Ganslmayer M, et al. Can quantitative tests of liver function discriminate between different etiologies of liver cirrhosis? Dig Dis Sci 2002; 47: 2669-73
-
(2002)
Dig Dis Sci
, vol.47
, pp. 2669-2673
-
-
Herold, C.1
Regn, S.2
Ganslmayer, M.3
-
24
-
-
0025314562
-
Effects of subchronic treatment with natural human interferons on antipyrine clearance and liver function in patients with chronic hepatitis
-
Echizen H, Ohta Y, Shirataki H, et al. Effects of subchronic treatment with natural human interferons on antipyrine clearance and liver function in patients with chronic hepatitis. J Clin Pharmacol 1990; 30: 562-7
-
(1990)
J Clin Pharmacol
, vol.30
, pp. 562-567
-
-
Echizen, H.1
Ohta, Y.2
Shirataki, H.3
-
25
-
-
0023244021
-
Hepatic clearance of D-sorbitol: Noninvasive test for evaluating functional liver plasma flow
-
Molino G, Cavanna A, Avagnina P, et al. Hepatic clearance of D-sorbitol: noninvasive test for evaluating functional liver plasma flow. Dig Dis Sci 1987; 32: 753-8
-
(1987)
Dig Dis Sci
, vol.32
, pp. 753-758
-
-
Molino, G.1
Cavanna, A.2
Avagnina, P.3
-
26
-
-
0017283739
-
Comparison of the half-life of antipyrine in plasma, whole blood and saliva of man
-
van Boxtel CJ, Wilson JT, Lindgren S, et al. Comparison of the half-life of antipyrine in plasma, whole blood and saliva of man. Eur J Clin Pharmacol 1976; 9: 327-32
-
(1976)
Eur J Clin Pharmacol
, vol.9
, pp. 327-332
-
-
van Boxtel, C.J.1
Wilson, J.T.2
Lindgren, S.3
-
27
-
-
0017325427
-
-
Horning MG, Brown L, Nowlin J, et al. Use of saliva in therapeutic drug monitoring. Clin Chem 1977; 23: 157-64 28. Baber N, Sweatman J. Clinical trials and good clinical practice. In: Griffin J, O'Grady J, editors. Textbook of pharmaceutical medicine. 4th ed. London: BMJ Books, 2002: 247-357
-
Horning MG, Brown L, Nowlin J, et al. Use of saliva in therapeutic drug monitoring. Clin Chem 1977; 23: 157-64 28. Baber N, Sweatman J. Clinical trials and good clinical practice. In: Griffin J, O'Grady J, editors. Textbook of pharmaceutical medicine. 4th ed. London: BMJ Books, 2002: 247-357
-
-
-
-
28
-
-
0037374404
-
Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites
-
Chalon SA, Desager JP, Desante KA, et al. Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites. Clin Pharmacol Ther 2003; 73: 178-91
-
(2003)
Clin Pharmacol Ther
, vol.73
, pp. 178-191
-
-
Chalon, S.A.1
Desager, J.P.2
Desante, K.A.3
-
29
-
-
0028022710
-
Determination of alfentanil and noralfentanil in human plasma by gas chromatography-mass spectrometry
-
Mautz DS, Labroo R, Kharasch ED. Determination of alfentanil and noralfentanil in human plasma by gas chromatography-mass spectrometry. J Chromatogr B Biomed Appl 1994; 658: 149-53
-
(1994)
J Chromatogr B Biomed Appl
, vol.658
, pp. 149-153
-
-
Mautz, D.S.1
Labroo, R.2
Kharasch, E.D.3
-
30
-
-
0026597118
-
Effects of different hepatic pathologies on disposition of alfentanil in anaesthetized patients
-
Bower S, Sear JW, Roy RC, et al. Effects of different hepatic pathologies on disposition of alfentanil in anaesthetized patients. Br J Anaesth 1992; 68: 462-5
-
(1992)
Br J Anaesth
, vol.68
, pp. 462-465
-
-
Bower, S.1
Sear, J.W.2
Roy, R.C.3
-
31
-
-
0027444634
-
Measuring lidocaine metabolite: Monoethylglycinexylidide as a quantitative index of hepatic function in adults with chronic hepatitis and cirrhosis
-
Huang YS, Lee SD, Deng JF, et al. Measuring lidocaine metabolite: monoethylglycinexylidide as a quantitative index of hepatic function in adults with chronic hepatitis and cirrhosis. J Hepatol 1993; 19: 140-7
-
(1993)
J Hepatol
, vol.19
, pp. 140-147
-
-
Huang, Y.S.1
Lee, S.D.2
Deng, J.F.3
-
32
-
-
0022642077
-
Pharmacokinetics and pharmacodynamics of intravenous midazolam in patients with severe alcoholic cirrhosis
-
MacGilchrist AJ, Birnie GG, Cook A, et al. Pharmacokinetics and pharmacodynamics of intravenous midazolam in patients with severe alcoholic cirrhosis. Gut 1986; 27: 190-5
-
(1986)
Gut
, vol.27
, pp. 190-195
-
-
MacGilchrist, A.J.1
Birnie, G.G.2
Cook, A.3
-
33
-
-
0023221080
-
Drug disposition in patients with HBsAg-positive chronic liver disease
-
Villeneuve JP, Thibeault MJ, Ampelas M, et al. Drug disposition in patients with HBsAg-positive chronic liver disease. Dig Dis Sci 1987; 32: 710-4
-
(1987)
Dig Dis Sci
, vol.32
, pp. 710-714
-
-
Villeneuve, J.P.1
Thibeault, M.J.2
Ampelas, M.3
-
34
-
-
0020398592
-
The pharmacokinetics of alfentanil (R39209): A new opioid analgesic
-
Bovill JG, Sebel PS, Blackburn CL, et al. The pharmacokinetics of alfentanil (R39209): a new opioid analgesic. Anesthesiology 1982; 57: 439-43
-
(1982)
Anesthesiology
, vol.57
, pp. 439-443
-
-
Bovill, J.G.1
Sebel, P.S.2
Blackburn, C.L.3
-
35
-
-
0022522046
-
The influence of hepatic plasma flow on alfentanil plasma concentration plateaus achieved with an infusion model in humans: Measurement of alfentanil hepatic extraction coefficient
-
Chauvin M, Bonnet F, Montembault C, et al. The influence of hepatic plasma flow on alfentanil plasma concentration plateaus achieved with an infusion model in humans: measurement of alfentanil hepatic extraction coefficient. Anesth Analg 1986; 65: 999-1003
-
(1986)
Anesth Analg
, vol.65
, pp. 999-1003
-
-
Chauvin, M.1
Bonnet, F.2
Montembault, C.3
-
36
-
-
0019981479
-
Comparative pharmacokinetics of fentanyl and alfentanil
-
Bower S, Hull CJ. Comparative pharmacokinetics of fentanyl and alfentanil. Br J Anaesth 1982; 54: 871-7
-
(1982)
Br J Anaesth
, vol.54
, pp. 871-877
-
-
Bower, S.1
Hull, C.J.2
-
37
-
-
0020045381
-
Drugs as indicators of hepatic function
-
Branch RA. Drugs as indicators of hepatic function. Hepatology 1982; 2: 97-105
-
(1982)
Hepatology
, vol.2
, pp. 97-105
-
-
Branch, R.A.1
-
38
-
-
0017165442
-
Propranolol disposition in chronic liver disease: A physiological approach
-
Branch RA, Shand DG. Propranolol disposition in chronic liver disease: a physiological approach. Clin Pharmacokinet 1976; 1: 264-79
-
(1976)
Clin Pharmacokinet
, vol.1
, pp. 264-279
-
-
Branch, R.A.1
Shand, D.G.2
-
39
-
-
0024261721
-
Determinants of hepatic function in liver cirrhosis in the rat: Multivariate analysis
-
Reichen J, Egger B, Ohara N, et al. Determinants of hepatic function in liver cirrhosis in the rat: multivariate analysis. J Clin Invest 1988; 82: 2069-76
-
(1988)
J Clin Invest
, vol.82
, pp. 2069-2076
-
-
Reichen, J.1
Egger, B.2
Ohara, N.3
|